02 July 2019

El Dr. Oriol Casanovas i la Dra. Iratxe Zuazo.

  • Càncer

Researchers at IDIBELL-ICO describe a new resistance mechanism to therapies that prevent the formation of blood vessels

•    In response to treatment, the immune cells of the tumor act as elements that make the tumor malignant.



01 July 2019
  • Càncer

Quantum technology and cancer. Research and application in its detection and treatment

The Centre de Cultura Contemporània of Barcelona (CCCB), with the collaboration of the Bellvitge Biomedical Research Institute (IDIBELL) and the program of Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), organized last 25th June 2019 a conference at the CCCB called "Quantum

27 June 2019

L'estudi de la UB i l’IDIBELL mostra que les connexions de la substància blanca del cervell són clau per entendre per què ens agrada o no la música.

  • Neurociències

Brain structure determines individual differences regarding music sensitivity

The white matter structure in the brain reflects music sensitivity, according to a study by the research group on Cognition and Brain Plasticity of the Institute of Neurosciences of the University of Barcelona (UB) and the Bellvitge Biomedical Research Institute (UB-IDIBELL).

26 June 2019

Tractivus team

  • Medicina Translacional

Tractivus raises 431,000 euros and consolidates its growth

Tractivus, the spin-off resulting from the collaboration between the Bellvitge Biomedical Research Institute (IDIBELL) and the Material Engineering Group (GEMAT) of IQS, consolidates its growth and the advancement of its technology.

25 June 2019
  • Neurociències

Distinct clinical profiles of Huntington's disease can be associated with two specific neural signatures

•    The identification of specific neural signatures can help develop specific biomarkers and personalized treatments for Huntington's disease.